IMUX Stock Summary and Trading Ideas (Immunic | NASDAQ:IMUX)

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic trades on the NASDAQ stock market under the symbol IMUX.

As of April 25, 2024, IMUX stock price declined to $1.21 with 53,616 million shares trading.

IMUX has a beta of 2.64, meaning it tends to be more sensitive to market movements. IMUX has a correlation of 0.14 to the broad based SPY ETF.

IMUX has a market cap of $109.00 million. This is considered a Micro Cap stock.

In the last 3 years, IMUX stock traded as high as $15.65 and as low as $.95.

The top ETF exchange traded funds that IMUX belongs to (by Net Assets): VXF, VTI, IWC, AVSC.

IMUX has underperformed the market in the last year with a price return of -20.4% while the SPY ETF gained +22.4%. However, in the short term, IMUX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.2% vs +3.0% return in SPY. But in the last 2 weeks, IMUX shares have been beat by the market, returning -12.9% compared to an SPY return of -3.0%.

IMUX support price is $1.18 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMUX stock will trade within this expected range on the day.